Renal function is associated with indicators of arsenic methylation capacity in Bangladeshi adults

Environmental Research

Volumn 143, Issue , 2015, Pages 123-130

  Peters, Brandilyn A ^a   Hall, Megan N ^a   Liu, Xinhua ^a   Slavkovich, Vesna ^a   Ilievski, Vesna ^a   Alam, Shafiul ^b   Siddique, Abu B ^b   Islam, Tariqul ^b   Graziano, Joseph H ^a   Gamble, Mary V ^a  

^a Department of Medicine   (United States)

^b Columbia University Arsenic Project in Bangladesh ^*  (Bangladesh)

Author keywords

Arsenic; Bangladesh; Glomerular filtration rate; Kidney; Methylation

Indexed keywords

ARSENIC; CACODYLIC ACID; CYSTATIN C; METHANEARSONIC ACID; DRINKING WATER; ORGANOARSENIC DERIVATIVE; WATER POLLUTANT;

ADULT; ARSENIC; BIOINDICATOR; BLOOD; DIGESTIVE SYSTEM; EPIDEMIOLOGY; EXCRETION; METABOLITE; METHYLATION; ORGANIC ACID; PARTICIPATORY APPROACH; PLASMA; PROTEIN; URINE;

ADULT; ARTICLE; BANGLADESHI; BLOOD; CHEMICAL MODIFICATION; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; METABOLITE; METHYLATION; PLASMA; PRIORITY JOURNAL; URINE; AGED; BANGLADESH; CHEMISTRY; DRUG EFFECTS; MIDDLE AGED; STATISTICAL MODEL; TOXICITY; WATER POLLUTANT;

BANGLADESH;

ADULT; AGED; ARSENIC; ARSENICALS; BANGLADESH; CACODYLIC ACID; CROSS-SECTIONAL STUDIES; DRINKING WATER; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; LINEAR MODELS; MALE; METHYLATION; MIDDLE AGED; WATER POLLUTANTS, CHEMICAL;

EID: 84944453779     PISSN: 00139351     EISSN: 10960953     Source Type: Journal    
DOI: 10.1016/j.envres.2015.10.001     Document Type: Article

References (42)

1. Atkins R.C. The epidemiology of chronic kidney disease. Kidney Int. Suppl. 2005, 67:S14-S18.
2. Barsoum R.S. Chronic kidney disease in the developing world. N. Engl. J. Med. 2006, 354:997-999.
3. Buchet J.P., et al. Comparison of the urinary excretion of arsenic metabolites after a single oral dose of sodium arsenite, monomethylarsonate, or dimethylarsinate in man. Int. Arch. Occup. Environ. Health 1981, 48:71-79.
4. Carter D.E., et al. The metabolism of inorganic arsenic oxides, gallium arsenide, and arsine: a toxicochemical review. Toxicol. Appl. Pharmacol. 2003, 193:309-334.
5. Challenger F. Biological methylation. Adv. Enzymol. Relat. Subj. Biochem. 1951, 12:429-491.
6. Chen Y., et al. A prospective study of arsenic exposure, arsenic methylation capacity, and risk of cardiovascular disease in Bangladesh. Environ. Health Perspect. 2013, 121:832-838.
7. Cheng Z., et al. Rapid multi-element analysis of groundwater by high-resolution inductively coupled plasma mass spectrometry. Anal. Bioanal. Chem. 2004, 379:512-518.
8. Cone E.J., et al. Normalization of urinary drug concentrations with specific gravity and creatinine. J. Anal. Toxicol. 2009, 33:1-7.
9. De Kimpe J., et al. 74As-arsenate metabolism in Flemish Giant rabbits with renal insufficiency. J. Trace Elem. Med. Biol. 1999, 13:7-14.
10. Delanaye P., et al. Normal reference values for glomerular filtration rate: what do we really know?. Nephrol. Dial. Transplant. 2012, 27:2664-2672.
11. Drobna Z., et al. Disruption of the arsenic (+3 oxidation state) methyltransferase gene in the mouse alters the phenotype for methylation of arsenic and affects distribution and retention of orally administered arsenate. Chem. Res. Toxicol. 2009, 22:1713-1720.
12. Gansevoort R.T., et al. Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. Lancet 2013, 382:339-352.
13. Ginsburg J.M., Lotspeich W.D. Interrelations of arsenate and phosphate transport in the dog kidney. Am. J. Physiol. 1963, 205:707-714.
14. Hall M., et al. Blood arsenic as a biomarker of arsenic exposure: results from a prospective study. Toxicology 2006, 225:225-233.
15. Hall M.N., et al. Chronic arsenic exposure and blood glutathione and glutathione disulfide concentrations in Bangladeshi adults. Environ. Health Perspect. 2013, 121:1068-1074.
16. Holm P.I., et al. Determination of choline, betaine, and dimethylglycine in plasma by a high-throughput method based on normal-phase chromatography-tandem mass spectrometry. Clin. Chem. 2003, 49:286-294.
17. Hsueh Y.M., et al. Urinary arsenic species and CKD in a Taiwanese population: a case-control study. Am. J. Kidney Dis. 2009, 54:859-870.
18. Huang Y.K., et al. Arsenic exposure, urinary arsenic speciation, and the incidence of urothelial carcinoma: a twelve-year follow-up study. Cancer Causes Control 2008, 19:829-839.
19. Huda M.N., et al. Prevalence of chronic kidney disease and its association with risk factors in disadvantageous population. Int. J. Nephrol. 2012, 2012:267329.
20. Hughes M.F. Arsenic toxicity and potential mechanisms of action. Toxicol. Lett. 2002, 133:1-16.
21. Hughes M.F., et al. Arsenic (+3 oxidation state) methyltransferase genotype affects steady-state distribution and clearance of arsenic in arsenate-treated mice. Toxicol. Appl. Pharmacol. 2010, 249:217-223.
22. Inker L.A., et al. Estimating glomerular filtration rate from serum creatinine and cystatin C. N. Engl. J. Med. 2012, 367:20-29.
23. Jacques P.F., et al. Serum total homocysteine concentrations in adolescent and adult Americans: results from the third National Health and Nutrition Examination Survey. Am. J. Clin. Nutr. 1999, 69:482-489.
24. Jafar T.H., et al. Level and determinants of kidney function in a South Asian population in Pakistan. Am. J. Kidney Dis. 2011, 58:764-772.
25. Lin S., et al. A NovelS-adenosyl-l-methionine:arsenic(III) methyltransferase from rat liver cytosol. J. Biol. Chem. 2002, 277:10795-10803.
26. National Kidney Foundation K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am. J. Kidney Dis. 2002, 39:S1-S266.
27. National Research Council Critical Aspects of EPA's IRIS Assessment of Inorganic Arsenic 2013, The National Academies Press, Washington, DC.
28. Peters B.A., et al. Creatinine, arsenic metabolism, and renal function in an arsenic-exposed population in Bangladesh. PLoS One 2014, 9:e113760.
29. Pfeiffer C.M., et al. Rapid and accurate HPLC assay for plasma total homocysteine and cysteine in a clinical laboratory setting. Clin. Chem. 1999, 45:290-292.
30. Reuter W., et al. Speciation of Five Arsenic Compounds in Urine by HPLC/ICP-MS 2003, PerkinElmer, Inc., Shelton, CT.
31. Shah A.D., et al. The association between body composition and cystatin C in South Asians: results from the MASALA study. Obes. Res. Clin. Pract. 2015, 9:180-183.
32. Steinmaus C., et al. Individual differences in arsenic metabolism and lung cancer in a case-control study in Cordoba, Argentina. Toxicol. Appl. Pharmacol. 2010, 247:138-145.
33. Styblo M., et al. The role of biomethylation in toxicity and carcinogenicity of arsenic: a research update. Environ. Health Perspect. 2002, 110(5):S767-S771.
34. Sweeney C.J., et al. A pharmacokinetic and safety study of intravenous arsenic trioxide in adult cancer patients with renal impairment. Cancer Chemother. Pharmacol. 2010, 66:345-356.
35. Tsukamoto H., et al. Metabolism and renal handling of sodium arsenate in dogs. Am. J. Vet. Res. 1983, 44:2331-2335.
36. Vahter M. Genetic polymorphism in the biotransformation of inorganic arsenic and its role in toxicity. Toxicol. Lett. 2000, 112-113:209-217.
37. Wang Y., et al. Analysis of acetylcholine, choline and butyrobetaine in human liver tissues by hydrophilic interaction liquid chromatography-tandem mass spectrometry. J. Pharm. Biomed. Anal. 2008, 47:870-875.
38. World Health Organization Guidelines for Drinking-water Quality - Volume 1: Recommendations 2008, WHO Press, Geneva, incorporating first and second addenda. Third edition.
39. Yan J., et al. MTHFR C677T genotype influences the isotopic enrichment of one-carbon metabolites in folate-compromised men consuming d9-choline. Am. J. Clin. Nutr. 2011, 93:348-355.
40. Zeisel S.H. Nutritional genomics: defining the dietary requirement and effects of choline. J. Nutr. 2011, 141:531-534.
41. Zheng L.Y., et al. Urine arsenic and prevalent albuminuria: evidence from a population-based study. Am. J. Kidney Dis. 2013, 61:385-394.
42. Zheng L.Y., et al. The association of urine arsenic with prevalent and incident chronic kidney disease: evidence from the Strong Heart Study. Epidemiology 2015, 26:601-612.